Group 1 - Jiangsu Hengrui Medicine Co., Ltd. has received approval from the National Medical Products Administration (NMPA) for clinical trials of HRS-7535 tablets, which are intended for the treatment of hypertension combined with overweight or obesity [1][2] - HRS-7535 is a novel oral small molecule GLP-1 receptor agonist that promotes insulin secretion and reduces glucagon secretion, while also enhancing satiety and suppressing appetite, making it suitable for treating type 2 diabetes and weight loss [2] - The total R&D investment for HRS-7535 has reached approximately 36.94 million yuan [2] Group 2 - The company's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has had its injectable SHR-1826 included in the list of breakthrough therapy drugs by the NMPA [5][6] - SHR-1826 is a therapeutic biological product targeting c-Met, intended for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer in patients who have failed at least one line of systemic therapy [6][7] - The total R&D investment for SHR-1826 has reached approximately 12.55 million yuan [7]

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has had its injectable SHR-1826 included in the list of breakthrough therapies by the National Medical Products Administration [1] Group 1: Product Information - SHR-1826 is an antibody-drug conjugate targeting c-Met, designed to specifically bind to tumor cell surface antigens and induce cell death upon internalization [1] - A similar product, ABBV-399 (generic name: telisotuzumab vedotin), received accelerated approval from the FDA in May 2025 for treating adult patients with advanced/metastatic non-squamous non-small cell lung cancer who have previously undergone systemic therapy and exhibit high expression of c-Met protein [1] Group 2: Financial Investment - The cumulative research and development investment related to SHR-1826 has reached approximately 125.5 million yuan [1]

药物临床试验登记与信息公示平台数据显示，广州百济神州生物制药有限公司的一项探索靶向 EGFR×MET 的抗体偶联药物 BG - C0902 单药治疗和与其他治疗药物联合用药治疗晚期实体瘤患者的安 全性、耐受性、药代动力学、药效学和初步抗肿瘤活性的1a/1b 期研究已启动。临床试验登记号为 CTR20255132，首次公示信息日期为 2026 年 1 月 5 日。 该药物剂型、用法用量暂未公示。本次试验主要目的为评价 BG - C0902 治疗晚期实体瘤患者的安全 性、耐受性、PK、药效学和初步抗肿瘤活性，研究分 2 个阶段进行：1a 期（剂量递增和安全性扩展） 和 1b 期（剂量扩展）。 责任编辑：小浪快报 （ORR）；1a 期和 1b 期缓解持续时间（DOR）和疾病控制率（DCR）；1b 期基于研究者使用 RECIST 1.1 版进行的肿瘤评估确定的无进展生存期（PFS）；1b 期发生不良事件和严重不良事件的患者数量； 1a 期和 1b 期 BG - C0902、总抗体和有效载荷 BGB - 40410 在规定时间点的浓度和其他 PK 参数；1a 期 和 1b 期通过检测抗药抗体（ADA）评价 BG - C ...

2025年12月，公司与Crescent Biopharma,Inc.就SKB105/CR-003与SKB118(程序性细胞死亡蛋白-1(PD-1)x 血管内皮生长因子(VEGF)双特异性抗体，亦称CR-001)达成战略合作，其中公司授予Crescent在美国、 欧洲及所有其他大中华地区(包括中国内地、香港、澳门及台湾)以外市场研究、开发、生产和商业化 SKB105/CR-003的独家权利，Crescent则授予公司在大中华地区研究、开发、生产和商业化SKB118/CR- 001的独家权利。公司计划于近期向中国国家药品监督管理局药品审评中心递交SKB118/CR-001的IND 申请。 科伦博泰生物-B(06990)发布公告，公司自主研发的靶向整合素β6(ITGB6)抗体偶联药物 (ADC)SKB105(亦称CR-003)的新药临床试验(IND)申请已获中国国家药品监督管理局(NMPA)药品审评中 心(CDE)批准，用于治疗晚期实体瘤。 ...

Investment Rating - The industry investment rating is "Overweight" [2] Core Insights - Antibody-drug conjugates (ADCs) have become one of the most promising and fastest-growing treatment methods, combining the precise targeting characteristics of antibody drugs with the strong cytotoxicity of small molecule drugs. ADCs show better clinical trial results compared to traditional chemotherapy, which has high off-target toxicity and increased risk of infection. The ADC market is expected to enter an explosive growth phase, with projections indicating a global market size of $115.1 billion by 2032 [5][22][68]. Summary by Sections ADC Drug Development - ADCs are characterized by their core components: highly effective cytotoxic drugs, specific monoclonal antibodies, and linkers that connect the two. The development of ADCs has made significant progress, with the first ADC approved by the FDA in 2000. The market for ADCs has grown rapidly from $2 billion in 2018 to $10.4 billion in 2023, with a CAGR of 38.6% [15][22]. ADC Industry Outlook - The ADC industry is experiencing high demand for outsourcing services, with an outsourcing rate of approximately 70%, significantly higher than the 34% for traditional biopharmaceuticals. The global ADC CXO market is projected to reach $11 billion by 2030, with a CAGR of 28.4% from 2022 to 2030 [6][31][69]. Key Companies - **WuXi AppTec**: A leading global CRDMO company in bioconjugates, with rapid revenue growth from $0.096 billion in 2020 to $4.052 billion in 2024, and a projected capital expenditure exceeding 7 billion RMB by 2029 [7][39]. - **Hao Yuan Medicine**: Focused on ADC development for over a decade, with over 90 ADC projects and more than 1,200 clients. The company has established a comprehensive ADC CDMO platform and is expanding its production capacity [7][53]. - **Easton Pharmaceuticals**: Provides a full range of CDMO services for ADCs and has supported multiple projects, including the first dual-load ADC project approved for clinical trials [8][61]. - **Kelaiying**: A leading CDMO that has entered the biopharmaceutical sector, with significant growth in ADC-related business and ongoing expansion of production capacity [9][64].

Core Viewpoint - Hansa Biopharma-B (03378.HK) has received approval from the National Medical Products Administration of the People's Republic of China to conduct clinical trials for its innovative drug, HX111, which is a first-in-class (FIC) OX40-targeted antibody-drug conjugate (ADC) [1] Group 1: Product Development - HX111 is identified as a first-in-class OX40-targeted ADC, which shows overexpression in several malignancies, including certain lymphomas, compared to normal tissues, making it a suitable target for ADC therapies [1] - Preclinical studies indicate that OX40 is a tumor-associated antigen (TAA) and is overexpressed in regulatory T cells (Treg) within the tumor microenvironment (TME), which are known to suppress anti-tumor immunity [1] - The mechanism of action (MOA) for HX111 involves the elimination of Tregs, representing a novel approach in cancer immunotherapy with potential applications across various cancers [1] Group 2: Company Strategy - HX111 is the third first-in-class molecule to advance to clinical development following the company's previous dual-specific antibody (BsAb) therapies, HX009 and HX044 [1] - The company aims to continue its efforts in clinical development to bring more innovative FIC drugs to market [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration of the People's Republic of China to conduct clinical trials for its innovative drug HX111, a first-in-class OX40-targeted antibody-drug conjugate (ADC) [1] Group 1: Product Development - HX111 is a first-in-class (FIC) OX40-targeted antibody-drug conjugate (ADC) [1] - Preclinical studies indicate that OX40 is overexpressed in several malignancies, including certain lymphomas, making it a suitable target for ADCs like HX111 [1] - OX40 is also overexpressed in regulatory T cells (Treg) within the tumor microenvironment (TME), which are known to suppress anti-tumor immunity [1] Group 2: Mechanism of Action - The elimination of Tregs represents a novel mechanism of action (MOA) for cancer immunotherapy, which can be achieved through HX111 [1] - HX111 has potential applications across various cancers due to its unique mechanism [1] Group 3: Future Development - HX111 is the third first-in-class molecule to advance to clinical development following HX009 and HX044, both of which are bispecific antibody therapies [1] - The company aims to continue its efforts in clinical development to bring more innovative FIC drugs to market [1]

Core Viewpoint - The announcement highlights a significant licensing agreement between Jiangsu Xiansheng Zaiming Pharmaceutical Co., Ltd. and Ipsen Pharma SAS, granting Ipsen exclusive global rights to develop, manufacture, and commercialize the antibody-drug conjugate SIM0613 outside Greater China, with potential financial benefits for the company totaling up to $1.06 billion [1]. Group 1 - Jiangsu Xiansheng has entered into an exclusive licensing agreement with Ipsen Pharma for the ADC SIM0613, targeting LRRC15 [1]. - The agreement includes an upfront payment of $45 million, along with milestone payments related to research, regulatory, and commercialization achievements, and tiered royalties on sales [1]. - SIM0613 is designed to target LRRC15, which is highly expressed in various solid tumors and tumor-associated fibroblasts, while showing minimal expression in normal cells [1]. Group 2 - The ADC SIM0613 is engineered to penetrate tumors and tumor-associated fibroblasts effectively, demonstrating significant tumor regression in various preclinical in vivo models [1]. - The potential total financial inflow of $1.06 billion includes various payment structures, indicating a strong commercial opportunity for Jiangsu Xiansheng [1].

Core Viewpoint - InnoCare Pharma-B (09606) shares rose by 10.19% to HKD 339.40, with a trading volume of HKD 135 million, following the announcement of Fast Track Designation (FTD) by the FDA for its new generation HER3-targeted antibody-drug conjugate DB-1310 for specific breast cancer patients [1] Group 1 - The FDA granted Fast Track Designation to DB-1310 for the treatment of adult patients with HR-positive, HER2-negative breast cancer who have previously undergone endocrine therapy and CDK4/6 inhibitor treatment, and are in the stage of unresectable or metastatic disease [1] - DB-1310 is the first HER3-ADC drug to receive FTD for this indication globally, indicating a significant milestone for the company [1] - The broad FTD indication for DB-1310 will facilitate its clinical development in both chemotherapy-naive and chemotherapy-resistant settings for HR+/HER2- breast cancer [1]

智通财经APP获悉，映恩生物-B(09606)早盘涨超3%，截至发稿，涨3.25%，报318港元，成交额2339.55 万港元。 消息面上，据映恩生物官微消息，12月18日，映恩生物宣布，美国食品药品监督管理局(FDA)已授予映 恩生物新一代靶向HER3抗体偶联新药DB-1310快速通道资格认定(Fast Track Designation，FTD)，用于 治疗曾接受过内分泌治疗、CDK4/6抑制剂治疗，且在不可切除或转移性疾病阶段接受或未接受过化 疗，或在完成辅助化疗期间或结束后6个月内出现疾病复发的成人晚期/不可切除或转移性激素受体(HR) 阳性、人表皮生长因子受体2(HER2)阴性(免疫组化0、1+或2+/原位杂交阴性)乳腺癌患者。 据悉，DB-1310成为全球首款在此适应症上获FTD的HER3-ADC药物。DB-1310在HR+/HER2-乳腺癌中 的FTD适应症范围较广，涵盖"在不可切除或转移性疾病阶段接受或未接受过化疗"的患者。这一广阔适 应症的FTD认定将有助于推动DB-1310在HR+/HER2-乳腺癌未经化疗前线场景与化疗耐药后线场景两条 主要路径上的关键临床开发。 ...